Manufacturer Supply of Dalbavancin CAS 171500-79-1 for Absssis Treatment

• Customization: Available
• CAS No.: 171500-79-1
• Formula: C88h100cl2n10o28
• Model NO.: 171500-79-1
• EINECS: 206-141-6
• Type: API
• Appearance: Powder
• Quality: Pharmaceutical Grade
• Colour: White
• Density: 1.59 g/cm3(Predicted)
• Storage: -20 Ceicius Degree
• Solubility: Slightly Soluble in Base, DMSO, and Water
• Melting Point: >160 Celsius Degree
• Transport Package: as Required
• Specification: USP-40
• Trademark: Worldyang
• Origin: China

Product Description

Dalbavancin
CAS: 171099-57-3
Appearance: White powder
Certifications: ISO9001:2015; GMP
Specifications: USP-40

Overview
Dalbavancin is a novel semi-synthetic glycopeptide antibiotic with superior efficacy compared to vancomycin, teicoplanin, linezolid, and quinupristin-dalfopristin, exhibiting lower minimum inhibitory concentrations (MICs) against various bacteria. With a prolonged half-life, it enables weekly intravenous administration to treat acute bacterial skin and skin structure infections (ABSSSI). Compared to other treatment options, Dalbavancin offers lower cross-resistance, reduced risk of antimicrobial resistance, and the convenience of single-dose therapy, significantly simplifying treatment and improving patient compliance.

Key Achievements

• Synthetic Biology Breakthrough: Our research team utilized synthetic biology techniques to reconstruct the biosynthetic system of the A40926 precursor-producing strain, achieving high-yield production. After synthesizing the precursor A40926, Dalbavancin was obtained through three-step chemical modifications (amideification at R3). The resulting active pharmaceutical ingredient (API) has a purity of ≥98%, with negligible homolog impurities. This project has been granted a Chinese invention patent, showcasing our proprietary innovation.
• Optimized Industrial Production: Dalbavancin is produced using A40926 fermented material. Key modifications include esterification protection of carboxy groups on amino glucuronic acid, amidation at the 38th position, and subsequent hydrolysis and salt formation. Challenges such as low fermentation yield, high homolog proportions, and by-product pigments were addressed through our application of synthetic biology principles.
  • Using Amycolatopsis balhimycina as the chassis, we mapped and rationally redesigned the metabolic pathway, improving A40926 yield by 2.66-fold to 702.4 mg/L in a 2 L fermenter. The proportion of A40926B0 in the total components reached 81.5%, enabling industrial-scale production.

Applications
Dalbavancin is specifically designed to treat skin and soft tissue infections caused by Gram-positive bacteria, including MRSA, MSSA, and resistant pathogens. With its convenient dosing regimen and robust pharmacokinetics, Dalbavancin is transforming treatment paradigms and reducing the burden on healthcare systems.